Company: MDCXW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001062993-25-010741
Chunk: 3

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-03
Form: 424B3
Chunk 3
---
ification obligations of the parties.

The Subscription Agreement contains customary representations, warranties, and agreements by the Company and the Investor, customary conditions to closing, and customary indemnification obligations of the Investor.

On June 2, 2025, the Company entered into a warrant agency agreement (the "Warrant Agency Agreement") with Odyssey Transfer and Trust Company ("Odyssey"), pursuant to which Odyssey will act as warrant agent with respect to the warrants issued by the Company in the Offering.

The foregoing descriptions of the Placement Agency Agreement, the Subscription Agreement, the warrants and the Warrant Agency Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such documents, copies of which are filed as Exhibits 1.1, 4.1, 4.2 and 4.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Item 3.02. Unregistered Sales of Equity Securities.

The information contained above in Item 1.01 is incorporated herein by reference.

Item 8.01 Other Events.

On May 29, 2025, the Company issued a press release announcing the pricing of the Offering and on June 2, 2025, the Company issued a press release announcing the closing of the Offering. Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein.

As previously disclosed in that certain Current Report on Form 8-K filed by the Company on May 5, 2025, the Company entered into a securities purchase agreement (the "Purchase Agreement") with YA II PN, Ltd. ("Yorkville") on May 2, 2025, in connection with the issuance and sale by the Company of debentures (the "Debentures") issuable in an aggregate principal amount of up to $5,000,000. Yorkville purchased and the Company issued a Debenture in aggregate principal amount of $1,250,000 upon the signing of the Purchase Agreement, for net proceeds to the company of $1,125,000. On June 2, 2025, Yorkville purchased and the Company issued an additional Debenture in the aggregate principal amount of $1,250,000, in connection with the filing of the Company's Registration Statement on May 27, 2025, for additional net proceeds to the Company of $1,125,000.

Item 9.